We've already seen half-a-dozen drugmaker deals worth around $100 billion in total this year. Despite a slew of mergers and acquisitions (M&A) over the past several months, there are still some cash-laden big biotechs and pharmaceutical companies eager to bulk up their development pipelines.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,